Form 8-K ACORDA THERAPEUTICS INC For: Jun 10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2022

 

Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Registrant’s Telephone Number, Including Area Code: (914) 347-4300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

---

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

Acorda Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 10, 2022 (the “Annual Meeting”) at the Hilton Garden Inn, 201 Ogden Avenue, Dobbs Ferry, NY 10522. 7,814,334 shares of the Company’s common stock, or 58.81% of the shares of the Company’s common stock issued and outstanding on the record date for the Annual Meeting, were present in person or represented by proxy at the Annual Meeting. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results of such voting:

Proposal One: Election of directors

 

As described in the Company’s 2022 Proxy Statement, the Company’s Board of Directors nominated one individual to serve as a Class I director for a term expiring on the date of the Company’s 2024 Annual Meeting of Stockholders, and two individuals to serve as Class II directors for a term expiring on the date of the Company’s 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified. All of such nominees were elected by a plurality vote in accordance with the Company’s Bylaws, as follows:

 

 

 

Proposal Two:  Approval of an amendment to the Acorda Therapeutics, Inc.2015 Omnibus Incentive Compensation Plan

 

The Company’s stockholders approved an amendment to the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan to increase the number of shares of common stock authorized thereunder and modify the fungible plan design, by the following vote:

 

 

 

Proposal Three:  Ratification of appointment of independent auditors

 

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent auditors for the fiscal year ending December 31, 2022, by the following vote:

 

 

 

Proposal Four: Advisory vote to approve named executive officer compensation

 

The Company’s stockholders voted, in an advisory, non-binding manner, to approve the compensation of the Company’s Named Executive Officers as disclosed in the Company’s 2022 Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “say-on-pay vote”). The Company’s stockholders voted as follows to approve such executive compensation pursuant to the say-on-pay vote:

 

 

 

 

---

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Acorda Therapeutics (ACOR) Announces Delisting
• First Phosphate Intersects 92.5 m of 11.82% Igneous Phosphate Starting at Surface at Its Begin-Lamarche Project in Saguenay-Lac-St-Jean, Quebec, Canada
• PARKS ASSOCIATES: CONNECTIONS™ TO ADDRESS GROWING ROLE OF AI IN THE SMART HOME